Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to €260 Million
CompanyDeals

Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to €260 Million

Lepu Biopharma Secures Conditional NMPA Approval for Becotatug Vedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma
CompanyDrug

Lepu Biopharma Secures Conditional NMPA Approval for Becotatug Vedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma

Eli Lilly and NVIDIA Forge Record‑Breaking AI‑Powered Supercomputer for Pharma
CompanyDeals

Eli Lilly and NVIDIA Forge Record‑Breaking AI‑Powered Supercomputer for Pharma

Shanghai Ark Biopharma Launches Phase II Trial of AK0610, a Next‑Generation RSV Prophylactic Antibody
CompanyDrug

Shanghai Ark Biopharma Launches Phase II Trial of AK0610, a Next‑Generation RSV Prophylactic Antibody

NovaBridge Biosciences Completes Rebranding, Launches New NBP Ticker on NASDAQ
Company

NovaBridge Biosciences Completes Rebranding, Launches New NBP Ticker on NASDAQ

Shanghai Junshi Biosciences Secures First Canadian Approval for LOQTORZI (Toripalimab) in Nasopharyngeal Cancer
Others

Shanghai Junshi Biosciences Secures First Canadian Approval for LOQTORZI (Toripalimab) in Nasopharyngeal Cancer

InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC
CompanyDrug

InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC

National Health Commission Unveils Fourth Drug List for Generic Development
Policy / Regulatory

National Health Commission Unveils Fourth Drug List for Generic Development

BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition
Company

BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition

GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth
Company

GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth

Sihuan Pharmaceutical Secures Fast‑Track Designation for NG‑350A in U.S. Rectal Cancer Treatment
CompanyDrug

Sihuan Pharmaceutical Secures Fast‑Track Designation for NG‑350A in U.S. Rectal Cancer Treatment

YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China
CompanyLegal / IP

YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China